HemostOD is a preclinical stage company developing a therapeutic platform inspired by platelet biology, allowing: - The production of in-vitro platelets as an alternative to unsatisfactory blood donor platelet transfusions - The production of HLA-null platelet to treat and prevent immune refractoriness in patients facing hypo proliferative thrombocytopenia - The production of siRNA/protein delivery solutions, exploiting natural platelets skills